Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q1 2023 · 10-Q
Revenue—
Net Income-$4.68M-$4.68MN/M vs Q1 2022 EPS Diluted-$2.31-$2.31no prior Q1 2022 on file Operating Income-$4,860,678N/M Operating Cash Flow-$5,137,009N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
Free Cash Flowderived-$5,142,178N/M ended Mar 31, 2023 · filed May 15, 2023 · 45 d after period end